Pds biotechnology corp (EDGE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities:
Net income (loss)

-6,998

-3,836

-50,859

-38,820

-28,078

-12,201

-6,883

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

3,139

866

6,182

5,305

2,899

1,297

260

Issuance of common stock from equity transaction

603

0

-

-

-

-

-

Stock-based 401K company common match

37

0

217

0

0

-

-

Depreciation expense

98

69

-

-

-

-

-

Impairment charge - IPR&D

2,974

0

-

-

-

-

-

Deferred income tax benefit

-381

0

-

-

-

-

-

Loss on extinguishment of debt

0

-185

-

-

-

-

-

Depreciation expense

-

-

182

100

53

31

4

Impairment of machinery and equipment

-

-

0

-

-

-

-

Loss on disposal of fixed assets

-310

0

-

-102

0

0

-

Amount of loss from lease termination write off of operating lease, right of use assets and operating lease liability.

32

0

-

-

-

-

-

Bargain purchase gain

13,334

0

-

-

-

-

-

Beneficial conversion charge

32

0

-

-

-

-

-

Increase in warrant liability

81

0

-

0

1,879

-582

854

Amortization of debt discount

-

-

32

75

104

35

0

Amortization of debt issuance costs

-

-

108

90

94

0

0

Non-cash interest expense

-

-

363

175

38

6

0

Changes in assets and liabilities:
Other receivable

-

-

-

-

-

-459

459

Prepaid expenses and other assets

1,138

35

32

-38

814

96

261

Accounts payable

-1,977

788

898

1,420

-71

526

-1,661

Accrued expenses and other liabilities

83

321

-

-

-

-

-

Accrued expenses

-

-

2,208

-676

2,142

808

100

Restructuring reserve

-1,572

0

0

-

-

-

-

Net cash used in operating activities

-18,073

-1,569

-40,696

-32,188

-21,752

-

-

Cash flows from investing activities:
Cash received in reverse merger transaction

29,106

0

-

-

-

-

-

Proceeds from sale of equipment

275

0

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-9,715

-8,044

Purchases of property and equipment

-

-

188

686

1,305

884

136

Net cash provided by investing activities

29,381

0

-188

-686

-1,305

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-

-

-884

-136

Proceeds from convertible note payable

-

-

-

-

-

-

100

Proceeds from issuance of debt

-

-

5,000

11,022

3,000

3,000

0

Proceeds from stock option exercise

0

132

118

293

1

0

0

Proceeds from exercise of warrants

0

99

53

20

0

0

-

Payments for issuance costs

-

-

-

544

1,402

1,351

0

Payments for debt back end fees

-

-

0

219

0

94

0

Repayments of debt

-

-

0

1,488

533

0

0

Proceeds from issuance of shares, gross

750

1,280

-

-

-

-

-

Repayments of capital lease obligation

0

15

-

-

-

-

-

Payments on note payable to stockholders

-

-

-

-

-

-

22

Proceeds from issuance of common stock, net of underwriting costs

-

-

17,382

0

86,059

0

0

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

0

52,394

14,917

15,821

Net cash provided by financing activities

750

1,497

22,554

9,084

139,518

-

-

Net increase in cash and cash equivalents

12,058

-72

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

16,470

15,899

Net decrease in cash

-

-

-18,331

-23,790

116,460

5,870

7,717

Supplemental disclosure of cash flow information:
Cash paid for:
Interest

0

1

1,635

790

559

-

-

Income taxes

0

0

-

-

-

-

-

Interest

-

-

-

-

-

82

0

Income taxes

-

-

-

-

-

-

1

Supplemental cash flow information:
Conversion of convertible notes and accrued interest into common stock

32

0

-

-

-

-

-

Consideration in connection with reverse merger transaction

15,793

0

-

-

-

-

-

Issuance of warrant in consideration for settlement agreement

372

0

-

-

-

-

-

Conversion of Preferred Stock to Common Stock

-

-

-

0

93,364

0

0

Conversion of Preferred Stock Warrants to Common Stock Warrants

-

-

-

0

3,726

0

0

Conversion of notes payable and accrued interest to preferred stock

-

-

-

-

-

-

253

Deferred issuance costs included in accrued expenses and accounts payable

-

-

-

0

549

53

0

Non-cash financing costs

-

-

-

0

175

0

0

Accrued capital expenditures included in accrued expenses and accounts payable

-

-

-

167

71

450

0